Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Coherus Oncology (CHRS) Gains from Sales and Divestitures (2017 - 2025)

Coherus Oncology's Gains from Sales and Divestitures history spans 11 years, with the latest figure at $528673.0 for Q4 2025.

  • For Q4 2025, Gains from Sales and Divestitures fell 81.08% year-over-year to $528673.0; the TTM value through Dec 2025 reached $528673.0, down 81.08%, while the annual FY2025 figure was $528673.0, 81.08% down from the prior year.
  • Gains from Sales and Divestitures for Q4 2025 was $528673.0 at Coherus Oncology, down from $2.8 million in the prior quarter.
  • Across five years, Gains from Sales and Divestitures topped out at $2.8 million in Q4 2024 and bottomed at $465930.0 in Q4 2021.
  • The 5-year median for Gains from Sales and Divestitures is $806854.0 (2022), against an average of $1.2 million.
  • The largest annual shift saw Gains from Sales and Divestitures skyrocketed 118.1% in 2024 before it plummeted 81.08% in 2025.
  • A 5-year view of Gains from Sales and Divestitures shows it stood at $465930.0 in 2021, then surged by 73.17% to $806854.0 in 2022, then soared by 58.75% to $1.3 million in 2023, then surged by 118.1% to $2.8 million in 2024, then plummeted by 81.08% to $528673.0 in 2025.
  • Per Business Quant, the three most recent readings for CHRS's Gains from Sales and Divestitures are $528673.0 (Q4 2025), $2.8 million (Q4 2024), and $1.3 million (Q4 2023).